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(57) ABSTRACT 
Halogenated diarylacetylenes, e.g., diarylacetylenes having 
at least one halo substituent in one aryl ring and an amine in 
the opposing aryl ring, can inhibit the proliferation of 
LSI 74T colon cancer cells through the inhibition of c-myc 
and induction of the cyclin-dependent kinase inhibitor-I 
(i.e., p21(Wifl/Cipl)). Such compounds are useful as anti­
neoplastic agents. 
12 Claims, 2 Drawing Sheets 
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HALOGENATED DIARYLACETYLENES AND 
METHODS OF TR EATING CANCER 
CROSS-REFERENCE TO RELATED 
APPLICATION 
2 
(I) 
This application claims the benefit of U.S. Provisional 
Application No. 61/970,657 filed Mar. 26, 2014 the entire 
disclosure of which is hereby incorporated by reference 10 
or a pharmaceutically acceptable salt thereof, wherein 
each ofX1 through X5 independently represents H, a lower 
alkyl, or halo, provided that at least one ofX1 through X5 is 
a halo; and each of Y 1 through Y5 independently represents 
herein. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
This invention was made with govermnent support under 
R21 CA139359 and ROI CAI 72379. The Govermnent has 
certain rights in the invention. 
TECHNICAL FIELD 
15 H, a lower alkyl, or NR1 R2, provided that at least one of Y 1 
through Y5 is NR1R2, wherein each of R1 and R2 indepen­
dently represents H, or a lower alkyl. In one aspect, of the 
present disclosure the compound of formula (I) does not 
include groups such as ester, hydroxyl, sulfonamide, amide, 
20 urethane, and carboxyl groups. 
The present disclosure relates to halogenated diarylacety-
lenes for use as antineoplastic agents. 25 
The halogenated diarylacetylenes of formula (I) or phar­
maceutically acceptable salts thereof can be included in a 
pharmaceutical composition with a pharmaceutically 
acceptable carrier. 
Another aspect of the present disclosure is directed to 
methods of treating cancer, e.g., inhibiting cancer cell 
growth and/or inhibiting tumor growth in a mammal, such as 
a human, or treating diseases associated with hyperprolif-
BACKGROUND 
A family of fluorinated N,N-dialkylaminostilbene analogs 
(FIDAS agents) that inhibit the expression of Wnt target 
genes, such as c-myc, and repress colon cancer cell growth 
in vitro and in vivo was recently described. See, e.g., J Med 
Chem 2011: 54:1288-1297; ACS Chem Biol 2013: 8(4):796-
803; U.S. Pat. No. 8,664,276. 
In addition, certain diarylacetylenes are known for certain 
medicinal uses. See, e.g., W02012149049; 
W02012149048; W02010092043; W02009038759; 
W02008073350; and W02001029011. Further, U.S. Pat. 
No. 8,716,355 to Tsai discloses hydroxylated tolans and 
related compounds in the treatment of cancer and Hadfield 
30 erating cells. In one embodiment of this aspect of the 
disclosure, an effective amount of one or more halogenated 
diarylacetylenes, pharmaceutical salts and/or pharmaceuti­
cal compositions thereof is administered to a patient in need 
of treatment of cancer sufficient to treat/inhibit cancer cell 
35 growth in the patient. 
In an embodiment of this aspect of the disclosure, a 
therapeutically effective amount of one or more halogenated 
diarylacetylenes, pharmaceutical salts and/or pharmaceuti­
cal compositions thereof is administered to a patient suffer-
40 ing from colorectal cancer. In another embodiment, a thera­
peutically effective amount of one or more halogenated 
diarylacetylenes, pharmaceutical salts and/or pharmaceuti­
cal compositions thereof is administered to a patient suffer-et al disclose preparation and evaluation of diarylalkynes as 
antitumor agents. Hadfield et al, Synthetic Communications 
1998: 28(8):1421-1431. However, there is an ongoing need 45 
for additional compounds that can be used to treat cancer 
and other ailments. 
ing from liver cancer or prostate cancer. 
Additional advantages of the present invention will 
become readily apparent to those skilled in this art from the 
following detailed description, wherein only the preferred 
embodiment of the invention is shown and described, simply 
by way of illustration of the best mode contemplated of SUMMARY OF THE DISCLOSURE 
Advantages of the present disclosure include halogenated 
diarylacetylenes and compositions having antineoplastic 
activity and methods of inhibiting cancer cell growth and/or 
treating cancer in a patient by administering one or more of 
the halogenated diarylacetylenes or pharmaceutical compo­
sitions thereof. 
50 carrying out the invention. As will be realized, the invention 
is capable of other and different embodiments, and its 
several details are capable of modifications in various obvi­
ous respects, all without departing from the invention. 
Accordingly, the drawings and description are to be regarded 
55 as illustrative in nature, and not as restrictive. 
One aspect of the present disclosure is directed to halo­
genated diarylacetylenes that are useful for killing hyper­
proliferating cells such as cancer cells for the treatment of 60 
human malignant and benign cancers, including without 
limitation, colorectal cancer (CRC), breast cancer, lung 
cancer, prostate cancer and liver cancer. In this aspect of the 
disclosure, there are provided certain halogenated diary­
lacetylenes having anti-neoplastic activity against cancerous 65 
cells. The halogenated diarylacetylenes of the present dis­
closure include compounds according to formula (I): 
BRIEF DESCRIPTION OF THE DRAWINGS 
Reference is made to the attached drawings, wherein 
elements having the same reference numeral designations 
represent similar elements throughout and wherein: 
FIG. 1 is a schematic illustration of the synthesis of 
halogenated diarylacetylenes 2. Reagents: a, 
HC CHC6H4Y; 0.5% Pd(PPh3)4, 1% Cul, H20, 75
° C., 1-2
h; b, a, HC CHC6H4NH2; 0.5% Pd(PPh3)4, 1 % Cul, H20, 
75° C., 1-2 h followed by CH3I, K2C03, acetone, 5 h, 56
° 
C.
US 9,895,324 B2 
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FIG. 2 is a blot showing inhibition of c-myc and induction 
of p21(Wifl/Cipl) by diarylacetylenes 2 in colon cancer 
cells. LS174T cells were treated with 1 µM of each diary­
lacetylenes 2 for 36 h. DMSO and 1 were used as control. 
Cell lysates were analyzed by western blotting with �-tu- 5 
bulin as a loading control. 
DETAILED DESCRIPTION OF THE 
DISCLOSURE 
4 
e.g., methyl, ethyl, or butyl groups. Preferably X1 and/or X5 
are halo groups, e.g., the diarylacetylenes have one or two
halogen substituents at ortho-positions relative to the acety-
lenic linkage, and X2 through X4 are H or a lower alkyl. In
some embodiments, the halogenated diarylacetylenes
include compounds, or a pharmaceutically acceptable salt
thereof, where Y3 is NR1R2, and Y1 , Y2, Y4, and Y5 
independently represent H, a lower alkyl, or NR1 R2 . In other
embodiments, Y3 is NR1R2, and Yi, Y2, Y4, and Y5 inde-
The present disclosure relates to halogenated diarylacety­
lenes, their salts and their pharmaceutical compositions and 
methods of inhibiting cancer cell growth and/or treating 
cancer in a patient by administering one or more of the 
halogenated diarylacetylenes, a pharmaceutical salt thereof, 
lO pendently represent H or a lower alkyl, e.g. Y1 , Y2, Y4, and
Y5 represent H. In still further embodiments, at least one of 
Ri, or R2, is a lower alkyl.
In another embodiment of the present disclosure, the 
halogenated diarylacetylenes include compounds according 
15 to formula (II): 
or a pharmaceutical composition thereof. It was found that 
halogenated diarylacetylenes having at least one, preferably 
two, halo substituents in one aryl ring and an amine in the 
opposing aryl ring, e.g., N-methylamino or N,N-dimethyl­
amino, inhibit the proliferation of LSI 74T colon cancer cells 20 
through the inhibition of c-myc and induction of the cyclin­
dependent kinase inhibitor-I (i.e., p21(Wifl/Cipl)). Such 
compounds and compositions are useful as antineoplastic 
agents. 
(II) 
or a pharmaceutically acceptable salt thereof, wherein Y3 
is NR1 R2, and Ri, R2, X1 through X5 and are as defined for
the compounds of formula (I) including the various embodi-
The halogenated diarylacetylenes of the present disclo- 25 
sure include at least one amine group, e.g., a primary, 
secondary or tertiary amine, on the aryl ring. Such com­
pounds are useful as antineoplastic agents and can be 
represented by the following formula: 
30 ments for formula (I). Preferably, at least one of R1 , or R2, 
is a lower alkyl and at least two ofX1 through X5 are either 
(i) a fluoro and chloro, (ii) both fluoro, (iii) both chloro
groups. In another embodiment, both Ri, and R2, are lower
alkyl, e.g., methyl, and at least two of X1 through X5 are 
(I) 
35 either: (i) a fluoro and chloro, (ii) both fluoro, (iii) both 
chloro groups. In some embodiments, X1 and/or X5 are halo 
groups, e.g., either a fluoro or chloro group. 
Pharmaceutical compositions of the present disclosure 
include one or more of compounds according to formula (I) 
or a pharmaceutically acceptable salt thereof. The sub­
stituents ofX1 through X5 each independently represent H, 
a lower alkyl, or halo, provided that at least one of X1 
through X5 is a halo. A halo group means an F, Cl, Br, I, or 
40 or a pharmaceutically acceptable salt thereof and a pharma­
ceutically acceptable carrier. Preferable, pharmaceutical 
compositions of the present disclosure include one or more 
of compounds according to formula (II) and a pharmaceu-
At group. Preferably substituents X1 through X5 include at 45 
least two halo groups, e.g., an F and/or Cl. Each of Y 1 
through Y5 independently represents H, a lower alkyl, or 
NR1R2, provided that at least one of Y1 through Y5 is
NR1 R2, wherein each of R1 and R2 independently represents
H, or a lower alkyl. In one aspect, of the present disclosure 50 
the compound of formula (I) does not include groups such 
as ester, hydroxyl, sulfonamide, amide, urethane, and car­
boxyl groups. 
The term "lower alkyl" includes saturated aliphatic 
groups, including straight-chain alkyl groups, branched- 55 
chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl sub­
stituted cycloalkyl groups, and cycloalkyl substituted alkyl 
groups having from one to about ten carbons (C1 -C10), e.g.,
from one to about six carbon atoms (C1 -C6) in its backbone 
structure. In one aspect of the present disclosure, the lower 60 
alkyl groups specifically include methyl, ethyl, propyl, iso­
propyl, n-butyl, etc. 
Embodiments of the halogenated diarylacetylenes of the 
present disclosure include wherein at least two ofX1 through 
X5 is are halo groups, e.g., wherein X1 through X5 is either 65 
(i) a fluoro and chloro, (ii) both fluoro, (iii) both chloro
groups, and wherein both R1 and R2 are lower alkyl groups,
tically acceptable carrier. 
In one aspect of the present disclosure, the compounds of 
formula (I) or (II), a pharmaceutically acceptable salt 
thereof, or a pharmaceutically acceptable composition 
thereof is used in the treatment of cancer. The method 
comprises administering to a patient in need of such treat­
ment an effective amount of one or more of the halogenated 
diarylacetylenes, a pharmaceutical salt thereof, or a phar-
maceutical composition thereof. Embodiments of the 
method include wherein the cancer treated is selected from 
the group consisting of colorectal cancer, breast cancer, lung 
cancer, prostate cancer and liver cancer. 
In the course of developing new agents for the treatment 
of cancers, we identified a family of fluorinated N,N­
dialkylaminostilbene analogs (FIDAS agents) that inhibit 
the expression of Wnt target genes, such as c-myc, and 
repress colon cancer cell growth in vitro and in vivo. 
Recently, we found that (E)-4-(2',6'-difluorostyryl)-N,N-
dimethylaniline (1) (FIG. 1) targeted exclusively the cata­
lytic subunit of methionine S-adenosyltransferase-2 (MAT-
2). See Zhang et al. ACS Chem Biol 2013: 8(4):796-803. 
MAT-2 serves as a source of S-adenosylmethionine (SAM) 
in colorectal and liver cancers where MAT-2 is upregulated. 
See 
US 9,895,324 B2 
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Cai et al. Hepatology 1996: 24:1090-1097; Chen et al. 
Gastroenterology 2007: 133:207-218; Ito et al. Surg Today 
2000: 30:706-710; and Liu et al. J Biol Chem 2011: 286: 
17168-17180. 
6 
sion and inducing the cell cycle inhibitor, p21(Wifl/Cipl). 
See Zhang et al. J Med Chem 2011: 54:1288-1297. The 
similarity of the diarylacetylenes to the stilbenes also 
It is believed that neoplastic tissues make effective use of 5 
SAM from this isoform of MAT to manage crucial epigen­
etic modifications of histone proteins and thereby regulate 
gene expression. Interference with this process would rep­
resent a new approach for developing potential antineoplas-
prompted an in silica modeling study of the binding of 
(E)-4-(2',6'-difluorostyryl)-N,N-dimethylaniline (1) and 
4((2,6-difluorophenyl)ethynyl)-N,N-dimethylaniline (2m). 
It was believed that para-oriented amino-substituents, such 
as the N-methylamino and N,N-dimethylamino groups, 
were associated with potent MAT2A inhibition. Using an 
artificially constructed homodimer of MAT2A, we observed 
that 1 and 2m bound to the same active site and that 
diarylacetylene 2m inhibited MAT2 at concentrations com­
parable to that of the stilbene 1 (data not shown). Variability 
tic agents. It is believed that the compounds of the present 10 
disclosure inhibit c-myc. In addition, the present compounds 
would avoid the facile E/Z-isomerizations that afflict the 
stilbenes and complicate pharmacodynamic and pharma­
cokinetic studies. 
The diarylacetylenes 2 (FIG. 1), e.g., compounds of 
formula (II), are a preferred group of halogenated diary­
lacetylenes. Prior reports of acetylenic compounds as anti­
neoplastic agents include monoalkylacetylenes from aquatic 
organisms and diarylacetylenic analogs of combrestatin. See 
Dembitsky et al. Nat. Prod. Commun. 2006: 1:773-812 and 
Hadfield et al. Synth. Commun. 1998: 28:1421-1431. The 
latter compounds showed cytotoxic activity against a murine 
leukemia cell line and one showed activity as an inhibitor of 
tubulin polymerization. The Sonogashira coupling of 4-(N, 
N-dimethylamino )phenylacetylene with various aryl iodides
provided access to the desired diarylacetylenes 2 (Table 1).
(Additional information about Sonogashira coupling can be
found in Bhattacharya et al. Sengupta, S. Tetrahedron Lett.
2004: 47:8733-8736 and Okura et al. J. Org. Chem. 1993:
58:4716-4721 ). Prior work from our laboratories established
that stilbenes with N-methylamino and N,N-dimethylamino
groups in a para-orientation relative to the central double
bond as well as 2,6-difluoro, 2-chloro-6-fluoro or 2,6-di­
chloro halogenation patterns in the other aromatic ring were
the most potent analogs in the inhibition of LSI 74T cell
proliferation. See Zhang et al. J Med Chem 2011: 54:1288-
1297.
Table 1 below provides IC50 values for the inhibition of 
LSI 74T cell proliferation for certain halogenated diary­
lacetylenes of the present disclosure and stilbene compound 
1 as shown in FIG. 1. 
TABLE 1 
15 in the MAT2A inhibition assay made the measurement of
c-myc inhibition a preferred analytical tool for assessing the
potency of diarylacetylenes.
We tested the effect of these diarylacetylenes 2 on the 
proliferation of LSI 74T colon cancer cells. The expression 
20 of c-myc and p21(Wifl/Cipl) were analyzed by western 
blotting (FIG. 2). The most active diarylacetylenes 2 inhib­
ited c-myc expression at 1 µM concentrations and as 
expected for a c-myc inhibitor, induced p21(wifl/Cipl) at 
the same time. Consistent with prior results in the stilbene 
25 family, the diarylacetylenes 2 lacking halogen substituents 
( e.g., 2c) or possessing only one fluorine substituent at a 
meta- or para-position relative to the acetylenic linkage ( e.g., 
2g) had very low potency (Table 1). Diarylacetylenes with 
one or two halogen substituents at ortho-positions relative to 
30 the acetylenic linkage ( e.g., 2b, 2d, 2e, 2m and 2n) possessed 
potencies as inhibitors of LSI 74T cell proliferation that 
exceeded that of the related stilbene 1 with IC50 values less 
than 50 nM (Table 1). Isomers of these diarylacetylenes 
35 (e.g., 2f, 2g, 2j and 2k) with halogens in meta- or para­
positions were significantly less active than the diarylacety­
lenes with ortho-halogens. Once again, these results are in 
consistent with the SAR findings in the stilbene family of 
c-myc inhibitors. Zhang et al. J Med Chem 2011: 54:1288-
40 1297. Finally, the N-methylation pattern in the diarylacety­
lenes suggested that N-methyl and N,N-dimethylaniline 
subunits led to equipotent inhibitors of c-myc (i.e., IC50 of 
2bssIC50 of 2m) but the desmethyl analog was considerably 
less active (IC50 of 2a=55±7.8 nm). 
Inhibition of 45 
LS174T Cell 
It was found that diarylacetylenes 2 have a dramatic effect 
on the proliferation of LS 17 4 T colon cancer cells by altering 
the expression of c-myc and thereby inducing p21(Wifl/ 
Cipl). These results are consistent with similar findings 
using halogenated stilbenes and suggest that diarylacety-
Compound 
2a 
2b 
2c 
2d 
2e 
2f 
2g 
2h 
2i 
2j 
2k 
21 
2m 
2n 
2o 
X1 
F 
F 
F 
F 
Cl 
F 
F 
F 
F 
F 
Cl 
X2 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
Cl 
Cl 
N(CH3)2 
NH2 
NHCH3 
N(CH3)2 
N(CH3)2 
N(CH3)2 
N(CH3)2 
N(CH3)2 
N(CH3)2 
N(CH3)2 
N(CH3)2 
N(CH3)2 
N(CH3)2 
N(CH3)2 
N(CH3)2 
N(CH3)2 
Proliferation 
IC50 (nM) 
59 ± 7.5 
55 ± 7.8 
23 ± 10.3 
>3000 
39 ± 6.0 
31 ± 3.1 
>3000 
>3000 
119 ± 4.6 
56 ± 8.1 
>3000 
>3000 
55 ± 6.0 
23 ± 6.0 
19 ± 5.0 
52 ± 7.1 
SAR studies were undertaken for those diarylacetylenes 2 
that possessed fluorine or chlorine substituents in one aryl 
ring and N-methylamino or N,N-dimethylamino in the other 
aryl ring. We reported previously that stilbenes repressed 
colon cancer cell proliferation by inhibiting c-myc expres-
50 lenes and stilbenes repress colon cancer proliferation 
through similar mechanisms. 
In an aspect of the present disclosure, the following 
particular halogenated diarylacetylenes and their pharma­
ceutical salts and pharmaceutical compositions can be used 
55 to treat cancer, CRC: 4-((2,6-Difluorophenyl)ethynyl)ani­
line (2a); 4-((2,6-Difluorophenyl)ethynyl)-N-methylaniline 
(2b ); N,N-Dimethyl-4-(phenylethynyl)aniline (2c ); 4-( (2-
Fluorophenyl)ethynyl)-N,N-dimethylaniline (2d); 4-((2-
Chlorophenyl)ethynyl)-N,N-dimethylaniline (2e); 4-((3-
60 Fluorophenyl)ethynyl)-N,N-dimethylaniline (2f); 4-((4-
Fluorophenyl)ethynyl)-N,N-dimethylaniline (2g); 4-((2,3-
Difluorophenyl)ethynyl)-N,N-dimethylaniline (2 h); 4-((2, 
4-Difluorophenyl)ethynyl)-N,N-dimethylaniline (2i); 4-((3,
4-Difluorophenyl)ethynyl)-N,N-dimethylaniline (2j); 4-((3,
65 5-Difluorophenyl)ethynyl)-N,N-dimethylaniline (2k); 4-((2, 
5-Difluorophenyl)ethynyl)-N,N-dimethylaniline (21); 4-((2,
6-Difluorophenyl)ethynyl)-N,N-dimethylaniline (2m), 
US 9,895,324 B2 
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4-( (2-Chloro-6-fluoropheny l)ethynyl )-N,N-dimethylaniline 
(2n), and/or 4-((2,6-Dichlorophenyl)ethynyl)-N,N-dimeth­
ylaniline (2o). 
8 
4-( (2, 6-Difluoropheny I )ethyny 1)-N-methylaniline 
(2b) 
To a solution of 200 mg (0.87 mmol) of 2a in acetone ( 4 
EXAMPLES 
The following examples are intended to further illustrate 
certain preferred embodiments of the invention and are not 
limiting in nature. Those skilled in the art will recognize, or 
5 mL) was added successively 145 mg (1.04 mmol, 1.2 equiv) 
of potassium carbonate and 161 mg (1.13 mmol, 1.3 equiv) 
of iodomethane. The mixture was refluxed for 5 h. After 
cooling, the product was diluted with water, extracted with 
be able to ascertain, using no more than routine experimen- 10 
tation, numerous equivalents to the specific substances and 
procedures described herein. 
Cell Proliferation Assay. 
LSI 74T cells were grown in RPMI medium (Mediatech) 
15 supplemented with 5% fetal bovine serum and 1 % penicil­
lin/streptomycin. For cell proliferation assays, 3xl04 cells/
well growing in 12-well plates were treated with DMSO or 
inhibitors. The cell numbers and viability were analyzed by 
Vi-Cell Cell Viability Analyzer after 4 days. The IC50 values 20 
were calculated with GraphPad Prim 5. 
Western Blotting. 
Western blot was performed as described previously1 . The
following antibodies were used: anti-c-myc (Epitomics, 
1472-1), anti-p21(Wifl/Cipl) (Cell Signaling, 2947), anti- 25 
�-tubulin (DSHB, E7). 
Materials. 
Chemicals were purchased from Sigma Aldrich or Fisher 
Scientific or were synthesized according to literature proce­
dures. Solvents were used from commercial vendors without 30 
further purification unless otherwise noted. Nuclear mag­
netic resonance spectra were determined on a Varian instru­
ment (1H, 400 MHz; 13C, 100 Mz). High resolution elec­
trospray ionization (ESI) mass spectra were recorded on a 
35 LTQ-Orbitrap Velos mass spectrometer (Thermo Fisher Sci-
entific, Waltham, Mass., USA). The FT resolution was set at 
100,000 (at 400 m/z). Samples were introduced through 
direct infusion using a syringe pump with a flow rate of 5 
µUmin. Purity of compounds was established by combus- 40 
tion analyses by Atlantic Microlabs, Inc., Norcross, Ga. 
Compounds were chromatographed on preparative layer 
Merck silica gel F254 unless otherwise indicated. 
Synthesis of Diarylacetylenes. 
A general procedure for the synthesis of diarylacetylenes 45 
2 involved the addition of 2.0 mmol of arylacetylene to a 
mixture of 2.1 mmol of an aryliodide, 3.0 mmol of diiso­
proprylethylamine, 0.02 mmol of Pd(PPh3)4, and 0.02 mmol 
of Cul in water (7 mL). The mixture was stirred for 1-2 h at 
75° C. After cooling, the product was collected by filtration 50 
or extracted using dichloromethane and purified by recrys­
tallization and/or chromatography. 
Characterization and Analytical Data Fordiarylacetylenes 2. 
dichloromethane, dried over MgS04 and concentrated. The 
product was purified by chromatography on silica gel using 
1:5ethyl acetate-hexane (Rf=0.48) to afford 68 mg (32%) of
2b. Mp 69-70° C. 1H NMR (CDCl3): Ii 7.40 (d, 2H, 1=8.8
Hz), 7.24-7.15 (m, lH), 6.92-6.87 (m, 2H), 6.53 (d, 2H, 
1=8.8 Hz), 3.95 (br s, lH), 2.84 (s, 3H). 13C NMR (CDCl3): 
Ii 162.92 (dd, 11=251.2 Hz, 12=5.3 Hz, two C), 149.92,
133.35 (two C), 128.77 (t, 1=9.8 Hz), 112.08 (two C), 111.25 
(dd, 11=19.0 Hz, 12=6.0 Hz, two C), 110.34, 103.39 (t, 
1=19.7 Hz), 100.89 (t, 1=3.1 Hz), 74.16, 30.48. HRMS (ESI) 
calcd for C15HuF2N [MH+]: 244.09323. Found: 244.09241. 
Anal. Calcd for C15HuF2N: C, 74.06; H, 4.56. Found: C, 
73.89; H, 4.71. 
N,N-Dimethyl-4-(phenylethynyl)aniline (2c) 
Purified by recrystallization from hexane. Yield 88%, mp 
104-106° C. 1H NMR (DMSO-d6): Ii 7.49-7.47 (m, 2H),
7.41-7.33 (m, SH), 6.71 (d, 2H, 1=9.2 Hz), 2.94 (s, 6H). 13C
NMR (DMSO-d6): Ii 150.10, 132.38 (two C), 130.86 (two
C), 128.61 (two C), 127.83, 123.29, 111.84 (two C), 108.41,
90.90, 87.16, 39.66 (two C). HRMS (ESI) calcd for
C16H15N [MH+]: 222.12773. Found: 222.12713. 
4-( (2-Fluoropheny l)ethyny 1)-N,N-dimethylaniline 
(2d) 
Purified by recrystallization from hexane. Yield 62%, mp 
94-96° C. 1H NMR (DMSO-d6): Ii 7.57-7.53 (m, lH), 
7.43-7.34 (m, 3H), 7.31-7.22 (m, lH), 7.24-7.20 (m, lH), 
6.71 (d, 2H, 1=9.2 Hz), 2.95 (s, 6H). 13C NMR (DMSO-d6): 
ll 161.47 (d, 1=246.7 Hz), 150.32, 132.96, 132.46 (two C), 
129.91 (d, 1=7.6 Hz), 124.64 (d, 1=3.8 Hz), 115.55 (d,
1=20.5 Hz), 111.81 (two C), 111.63 (d, 1=15.2 Hz), 107.83, 
96.02 (d, 1=3.0 Hz), 80.38, 39.62 (two C). HRMS (ESI) 
calcd for C16H14FN [MH+]: 240.11830. Found: 240.11726. 
Anal. Calcd for C16H14FN: C, 80.31; H, 5.90. Found: C,
80.04; H, 6.03. 
4-((2-Chlorophenyl)ethynyl)-N,N-dimethylaniline 
(2e) 
Purified by recrystallization from ethanol. Yield 56%, mp 
108-110° C. 1H NMR (DMSO-d6): Ii 7.60-7.54 (m, 2H),
7.38-7.34 (m, 4H), 6.73 (d, 2H, 1=8.8 Hz), 2.96 (s, 6H). 13C
NMR (DMSO-d6): ll 150.40, 134.00, 133.33, 132.76, 132.55
4-((2,6-Difluorophenyl)ethynyl)aniline (2a) 55 (two C), 129.28, 127.27, 122.96, 111.85 (two C), 107.80, 
96.27, 84.08, 39.67 (two C). HRMS (ESI) calcd for 
C16H14CIN [MH+]: 256.08875. Found: 256.08805. Purified by chromatography on silica gel using 1:2ethyl 
acetate-hexane (Rf=0.43). Yield 65%, mp 104-105° C. 
1H
NMR (DMSO-d6): Ii 7.46-7.39 (m, lH), 7.22 (d, 2H, 1=8.8
Hz), 7.20-7.16 (m, 2H), 6.58 (d, 2H, 1=8.8 Hz), 5.69 (s, 2H, 60 
NH2). 
13C NMR (DMSO-d6): Ii 161.72 (dd, 11=248.9 Hz,
12=5.3 Hz, two C), 150.21, 132.77 (two C), 129.89 (t, 1=9.9 
Hz), 113.60 (two C), 111.68 (dd, 11=18.2 Hz, 12=6.l Hz, two 
C), 106.96, 101.96 (t, 1=19.8 Hz), 102.28 (d, 1=2.7 Hz), 
73.11. HRMS (ESI) calcd for C14H9F2N [MH+]: 230.07758. 65 
Found: 230.07660. Anal. Calcd for C14H9F2N: C, 73.36; H, 
3.96. Found: C, 73.10; H, 4.03. 
4-( (3-Fluoropheny l)ethyny 1)-N,N-dimethylaniline 
(2f) 
Purified by recrystallization from hexane. Yield 87%, mp 
99-100° C. 1H NMR (DMSO-d6): Ii 7.45-7.31 (m, SH),
7.22-7.17 (m, lH), 6.71 (d, 2H, 1=9.2 Hz), 2.95 (s, 6H). 13C
NMR (DMSO-d6): ll 161.90 (d, 1=242.8 Hz), 150.30, 132.55
(two C), 130.66 (d, 1=8.4 Hz), 127.19 (d, 1=2.2 Hz), 125.32
(d, 1=9.9 Hz), 117.31 (d, 1=22.7 Hz), 115.02 (d, 1=21.3 Hz),
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111.81 (two C), 107.79, 92.09, 86.07 (d, 1=3.0 Hz), 39.64 
(two C). HRMS (ESI) calcd for C16H14FN [MH+]: 
240.11830. Found: 240.11750. Anal. Calcd for C16H14FN: 
C, 80.31; H, 5.90. Found: C, 80.03; H, 6.10. 
10 
Hz), 7.28-7.19 (m, 3H), 6.71 (d, 2H, 1=9.2 Hz), 2.96 (s, 6H). 
13C NMR (DMSO-d6): ll 162.27 (dd, \=245.1 Hz, 12=14.4 
Hz, two C), 150.47, 132.70 (two C), 126.29 (t, 1=12.1 Hz), 
113.95 (dd, 11=19.0 Hz, 12=7.6 Hz, two C), 111.78 (two C), 
4-( ( 4-Fluoropheny l)ethyny 1)-N,N-dimethy !aniline 
(2g) 
5 107.22, 103.94 (t, 1=25.8 Hz), 93.42, 85.33 (t, 1=3.8 Hz), 
39.60 (two C). HRMS (ESI) calcd for C16H13F2N [MH+]: 
258.10888. Found: 258.10787. Anal. Calcd for C16H13F2N: 
Purified by recrystallization from methanol. Yield 92%, 
mp 132-134° C. 1H NMR (DMSO-d6): ll 7.54-7.51 (m, 2H), 
7.35 (d, 2H, 1=8.8 Hz), 7.24-7.20 (m, 2H), 6.70 (d, 2H, 1=9.2 10 
Hz), 2.94 (s, 6H). 1
3
C NMR (DMSO-d6): Ii 161.47 (d, 
1=245.l Hz), 150.12, 133.07 (d, 1=8.4 Hz, two C), 132.35 
(two C), 119.74 (d, 1=3.8 Hz), 115.80 (d, 1=22.1 Hz, two C), 
111.83 (two C), 108.26, 90.56, 86.07, 39.65 (two C). HRMS 
(ESI) calcd for C16H14FN [MH+]: 240.11830. Found: 15 
240.11752. 
4-((2,3-Difluorophenyl)ethynyl)-N,N-dimethylani­
line (2 h) 
C, 74.69; H, 5.09. Found: C, 74.43; H, 5.20. 
4-((2,5-Difluorophenyl)ethynyl)-N,N-dimethylani­
line (21) 
Purified by recrystallization from methanol. Yield 79%, 
mp 106-107° C. 1H NMR (DMSO-d6): ll 7.45-7.41 (m, lH), 
7.39-7.32 (m, 3H), 7.28-7.22 (m, lH), 6.72 (d, 2H, 1=9.2
Hz), 2.96 (s, 6H). 1
3
C NMR (DMSO-d6): Ii 157.89 (dd, 
\=243.6 Hz, 12=2.3 Hz), 157.80 (dd, \=239.9 Hz, 12=2.3
Hz), 150.52, 132.62 (two C), 118.82 (d, 1=25.8 Hz), 117.04 
(dd, 11=24.3 Hz, 12=9.l Hz), 116.53 (dd, 11=24.3 Hz, 12=8.3 
20 Hz), 113.01 (dd, 11=18.2 Hz, 12=10.7 Hz), 111.80 (two C), 
107.23, 97.22 (d, 1=3.8 Hz), 79.61, 39.61 (two C). HRMS 
(ESI) calcd for C16H13F2N [MH+]: 258.10888. Found: 
258.10812. Anal. Calcd for C16H13F2N: C, 74.69; H, 5.09. 
Purified by recrystallization from methanol. Yield 65%, 
mp 104-106° C. 1H NMR (DMSO-d6): ll 7.46-7.37 (m, 4H),
7.24-7.19 (m, lH), 6.72 (d, 2H, 1=8.0 Hz), 2.91 (s, 6H). 1
3
C 
NMR (DMSO-d6): ll 149.78 (dd, 11=244.4 Hz, 12=11.4 Hz), 
149.37 (dd, 11=247.1 Hz, 12=13.8 Hz), 132.62 (two C), 25 
128.15 (d, 1=4.0 Hz), 125.14 (d, 1=4.6 Hz), 125.06 (d, 1=4.6
Hz), 117.21 (d, 1=16.7 Hz), 113.87 (d, 1=11.4 Hz), 111.80 
(two C), 107.20, 97.54 (d, 1=3.8 Hz), 79.23 (d, 1=4.6 Hz), 
39.60 (two C). HRMS (ESI) calcd for C16H13F2N [MH+]: 
258.10888. Found: 258.10818. Anal. Calcd for C16H13F2N: 
C, 74.69; H, 5.09. Found: C, 74.43; H, 5.22. 30 
4-((2,4-Difluorophenyl)ethynyl)-N,N-dimethylani­
line (2i) 
Found: C, 74.56; H, 5.21. 
4-((2,6-Difluorophenyl)ethynyl)-N,N-dimethylani­
line (2m) 
Purified by recrystallization from hexane. Yield 59%, mp 
98-100° C. 1H NMR (DMSO-d6): ll 7.49-7.41 (m, lH), 7.37
(d, 2H, 1=8.8 Hz), 7.23-7.18 (m, 2H), 6.72 (d, 2H, 1=8.8 Hz),
2.97 (s, 6H). 1
3
C NMR (DMSO-d6): ll 161.75 (dd, 11=248.9
Hz, 12=5.3 Hz, two C), 150.58, 132.59 (two C), 130.12 (t,
1=10.3 Hz), 111.76 (dd, 11=17.9 Hz, 12=4.3 Hz, two C), 
35 111.82 (two C), 107.21, 101.83 (t, 1=19.8 Hz), 100.88 (t, 
1=3.l Hz), 73.83, 39.64 (two C). HRMS (ESI) calcd for 
C16H13F2N [MH+]: 258.10888. Found: 258.10801. Anal. 
Calcd for C16H13F2N: C, 74.69; H, 5.09. Found: C, 74.47; 
H, 5.24. 
Purified by recrystallization from methanol. Yield 82%, 
mp 116-118° C. 1H NMR (DMSO-d6): ll 7.65-7.59 (m, lH), 
7.40-7.34 (m, 3H), 7.15-7.11 (m, lH), 6.71 (d, 2H, 1=9.2
Hz), 2.95 (s, 6H). 1
3
C NMR (DMSO-d6): Ii 161.79 (dd, 
11=249.3 Hz, 12=12.5 Hz), 150.35, 161.63 (dd, 11=247.8 Hz, 
12=11.8 Hz), 134.11 (dd, 11=9.8 Hz, 12=2.3 Hz), 132.44 (two 40 
C), 112.15 (dd, 11=22.0 Hz, 12=3.8 Hz), 111.81 (two C), 
108.31 (dd, 11=15.6 Hz, 12=4.2 Hz), 107.68, 104.50 (t, 
1=25.8 Hz), 95.75, 79.35, 39.63 (two C). HRMS (ESI) calcd 
for C16H13F2N [MH+]: 258.10888. Found: 258.10806. 
Anal. Calcd for C16H13F2N: C, 74.69; H, 5.09. Found: C, 45 
74.61; H, 5.23. 
4-((3,4-Difluorophenyl)ethynyl)-N,N-dimethylani­
line (2j) 
4-( (2-Chloro-6-fluoropheny l)ethynyl )-N,N-dimeth­
y laniline (2n) 
Purified by chromatography on silica gel using 1:5ethyl 
acetate-hexane (Rf
=0.74). Yield 53%, mp 86-88° C. 1H
NMR (DMSO-d6): Ii 7.45-7.30 (m, SH), 6.73 (d, 2H, 1=8.8 
Hz), 2.97 (s, 6H). 1
3
C NMR (DMSO-d6): Ii 161.89 (d, 
1=249.7 Hz), 150.62, 135.11 (d, 1=3.0 Hz), 132.64 (two C), 
129.90 (d, 1=9.1 Hz), 125.37 (d, 1=3.0 Hz), 114.37 (d, 
50 1=21.2 Hz), 112.37 (d, 1=18.2 Hz), 111.84 (two C), 107.24, 
101.55 (d, 1=3.8 Hz), 77.59, 39.64 (two C). HRMS (ESI) 
calcd for C16H13CIFN [MH+]: 274.07933. Found: 
274.07858. Anal. Calcd for C16H13CIFN: C, 70.20; H, 4.79. 
Found: C, 70.43; H, 4.76. 
Purified by recrystallization from methanol. Yield 93%, 
mp 100-101 ° C. 1H NMR (DMSO-d6): ll 7.60-7.55 (m, lH), 
7.48-7.41 (m, lH), 7.37-7.32 (m, 3H), 6.71 (d, 2H, 1=9.2
Hz), 2.95 (s, 6H). 1
3
C NMR (DMSO-d6): Ii 150.29, 149.21 
(dd, 11=249.0 Hz, 12=14.5 Hz, two C), 132.49 (two C), 55 
128.26 (dd, 11=6.4 Hz, 12=3.4 Hz), 128.68 (dd, 11=8.0 Hz, 
12=4.2 Hz), 119.76 (d, 1=18.2 Hz), 118.00 (d, 1=16.7 Hz), 
111.80 (two C), 107.69, 91.58, 85.21, 39.62 (two C). HRMS 
(ESI) calcd for C16H13F2N [MH+]: 258.10888. Found: 
258.10787. Anal. Calcd for C16H13F2N: C, 74.69; H, 5.09. 60 
Found: C, 74.80; H, 5.11. 
4-((3,5-Difluorophenyl)ethynyl)-N,N-dimethylani­
line (2k) 
Purified by recrystallization from methanol. Yield 84%, 
mp 72-74° C. 1H NMR (DMSO-d6): Ii 7.37 (d, 2H, 1=8.8 
4-( (2, 6-Dichlorophenyl )ethyny I )-N,N-dimethy !ani­
line (2o) 
Purified by recrystallization from ethanol. Yield 54%, mp 
96-98° C. 1H NMR (DMSO-d6): Ii 7.52 (d, 2H, 1=8.0 Hz),
7.37-7.29 (m, 3H), 6.70 (d, 2H, 1=9.2 Hz), 2.93 (s, 6H). 1
3
C 
NMR (DMSO-d6): Ii 150.66, 135.26, 133.31, 132.67 (two 
C), 129.40, 127.97 (two C), 122.79, 111.82 (two C), 107.22, 
101.91, 81.62, 39.61 (two C). HRMS (ESI) calcd for 
65 C16H13Cl2N [MH+]: 290.04978. Found: 290.04888. Anal. 
Calcd for C16H13Cl2N: C, 66.22; H, 4.52. Found: C, 66.06; 
H, 4.70. 
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Only the preferred embodiment of the present invention 
and examples of its versatility are shown and described in 
the present disclosure. It is to be understood that the present 
invention is capable of use in various other combinations 
and environments and is capable of changes or modifications 5 
within the scope of the inventive concept as expressed 
herein. Thus, for example, those skilled in the art will 
recognize, or be able to ascertain, using no more than routine 
experimentation, numerous equivalents to the specific sub­
stances, procedures and arrangements described herein. 10 
Such equivalents are considered to be within the scope of 
this invention, and are covered by the following claims. 
What is claimed is: 
1. A method of treating colorectal cancer, the method 15 
comprising administering to a patient in need of such 
treatment an effective amount of a compound according to 
the following formula: 
20 
(I) 
25 
12 
5. The method of claim 4, wherein either X1 or X5 or both
X1 and X5 are halo groups and X2 through X4 are H or a
lower alkyl. 
6. The method of claim 1, wherein X1 and/or X5 are halo
groups, X2 through X4 are H or a lower alkyl, Y3 is NR1R2, 
and Y 1 , Y 2, Y 4, and Y 5 independently represent H or a lower 
alkyl. 
7. The method of claim 1, wherein X1 and/or X5 are fluoro
and/or chloro and at least one of R1 or R2 is a lower alkyl. 
8. A pharmaceutical composition comprising a therapeu­
tically effective amount of a compound according to the 
following formula: 
or a pharmaceutically acceptable salt thereof, wherein 
each of X1 through X5 independently represents H, a 
lower alkyl, a fluoro or a chloro, provided that at least 
one ofX1 through X5 is a fluoro or chloro; and each of 
Y1 through Y5 independently represents H, a lower 
alkyl, or NR1 R2, provided that at least one of Y 1 
through Y5 is NR1R2, wherein each of R1 and R2 
independently represents H, or a lower alkyl, provided 
that at least one of R1 or R2 is a lower alkyl; and a 
pharmaceutically acceptable carrier, wherein the phar­
maceutical composition is acceptable to be adminis­
tered to a mammal. 
or a pharmaceutically acceptable salt thereof, wherein 30 
each of X1 through X5 independently represents H, a 
lower alkyl, or halo, provided that at least one of X1 
through X5 is a halo; and each of Y1 through Y5 
independently represents H, a lower alkyl, or NR1R2, 
provided that at least one ofY1 through Y5 is NR1R2, 
wherein each ofR1 and R2 independently represents H, 
9. The pharmaceutical composition of claim 8, wherein at
35 least two ofX1 through X5 are fluoro, or chloro groups and 
the remaining X1 through X5 are H. or a lower alkyl, provided that at least one of R1 or R2 
is a lower alkyl. 
2. The method of claim 1, wherein at least two of X1 
through X5 are halo groups. 
3. The method of claim 2, wherein X1 through X are
either (i) a fluoro and chloro, (ii) both fluoro, or (iii) 
5
both 
chloro groups. 
4. The method of claim 1, wherein both R1 and R2 are
lower alkyl groups. 
10. The pharmaceutical composition of claim 8, wherein
X1 and X5 are either (i) a fluoro and chloro, (ii) both fluoro,
(iii) both chloro groups.
40 11. The pharmaceutical composition of claim 8, wherein
at least one of R1 , or R2, is a lower alkyl.
12. The pharmaceutical composition of claim 11, wherein
the lower alkyl is methyl or ethyl. 
* * * * *
